Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Failure to Preserve beta-Cell Function With Mycophenolate Mofetil and Daclizumab Combined Therapy in Patients With New-Onset Type 1 Diabetes DIABETES CARE Gottlieb, P. A., Quinlan, S., Krause-Steinrauf, H., Greenbaum, C. J., Wilson, D. M., Rodriguez, H., Schatz, D. A., Moran, A. M., Lachin, J. M., Skyler, J. S. 2010; 33 (4): 826-832

Abstract

This trial tested whether mycophenolate mofetil (MMF) alone or with daclizumab (DZB) could arrest the loss of insulin-producing beta-cells in subjects with new-onset type 1 diabetes.A multi-center, randomized, placebo-controlled, double-masked trial was initiated by Type 1 Diabetes TrialNet at 13 sites in North America and Europe. Subjects diagnosed with type 1 diabetes and with sufficient C-peptide within 3 months of diagnosis were randomized to either MMF alone, MMF plus DZB, or placebo, and then followed for 2 years. The primary outcome was the geometric mean area under the curve (AUC) C-peptide from the 2-h mixed meal tolerance test.One hundred and twenty-six subjects were randomized and treated during the trial. The geometric mean C-peptide AUC at 2 years was unaffected by MMF alone or MMF plus DZB versus placebo. Adverse events were more frequent in the active therapy groups relative to the control group, but not significantly.Neither MMF alone nor MMF in combination with DZB had an effect on the loss of C-peptide in subjects with new-onset type 1 diabetes. Higher doses or more targeted immunotherapies may be needed to affect the autoimmune process.

View details for DOI 10.2337/dc09-1349

View details for Web of Science ID 000276793200029

View details for PubMedID 20067954

View details for PubMedCentralID PMC2845036